Helix BioPharma Corp.
HBP.TOTSXHealthcare● Active
$1.53
$-0.05(-3.16%)
Market Cap$116858490
P/E Ratio—
52W High$5.4
52W Low$0.84
Helix BioPharma Corp. (HBP.TO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HBP.TO · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 16, 2026EPS Actual
-$0.01
Est. -$0.10 · +90.9%
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 16, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
HBP.TO reports quarterly as a TSX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | Jun 15, 2026 | -$0.10 | — | — | — | — | — |
| ▲ Q1 FY2026 | Mar 16, 2026 | -$0.10 | -$0.01 | +90.9% | — | — | — |
| — Q4 FY2025 | Dec 12, 2025 | — | -$0.01 | — | — | — | — |
| — Q4 FY2025 | Oct 29, 2025 | — | -$0.01 | — | — | — | — |
| — Q2 FY2025 | Jun 16, 2025 | — | -$0.15 | — | — | — | — |
| — Q1 FY2025 | Mar 14, 2025 | — | -$0.14 | — | — | — | — |
| — Q4 FY2024 | Dec 12, 2024 | — | -$0.14 | — | — | — | — |
| — Q4 FY2024 | Oct 24, 2024 | — | -$0.11 | — | — | — | — |
Q2 FY2026
Jun 15, 2026
EPS Actual
—
EPS Est.
-$0.10
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 16, 2026Beat
EPS Actual
-$0.01
EPS Est.
-$0.10
EPS Surpr.
+90.9%
Revenue
—
Q4 FY2025
Dec 12, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2025
Oct 29, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
Jun 16, 2025
EPS Actual
-$0.15
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 14, 2025
EPS Actual
-$0.14
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Dec 12, 2024
EPS Actual
-$0.14
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Oct 24, 2024
EPS Actual
-$0.11
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q2 FY2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q1 FY2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q4 FY2026 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q3 FY2026 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q2 FY2026 | $-0.10 | $-0.10 | $-0.10 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 16, 2026 | +90.9% | $1.99 | $1.79 | -10.05% |
| — Q4 FY2025 | Dec 12, 2025 | — | $2.13 | $2.04 | -4.23% |
| — Q4 FY2025 | Oct 29, 2025 | — | $2.09 | $2.17 | +3.83% |
| — Q2 FY2025 | Jun 16, 2025 | — | $0.93 | $0.91 | -2.15% |
| — Q1 FY2025 | Mar 14, 2025 | — | $0.88 | $0.90 | +2.27% |
| — Q4 FY2024 | Dec 12, 2024 | — | $0.87 | $0.87 | +0.00% |
| — Q4 FY2024 | Oct 24, 2024 | — | $1.09 | $1.13 | +3.67% |
| — Q2 FY2024 | May 13, 2024 | — | $1.15 | $1.15 | +0.00% |
Q1 FY2026-10.05%
Report Date
Mar 16, 2026
EPS Beat/Miss
+90.9%
Price Before
$1.99
Price After
$1.79
Q4 FY2025-4.23%
Report Date
Dec 12, 2025
EPS Beat/Miss
—
Price Before
$2.13
Price After
$2.04
Q4 FY2025+3.83%
Report Date
Oct 29, 2025
EPS Beat/Miss
—
Price Before
$2.09
Price After
$2.17
Q2 FY2025-2.15%
Report Date
Jun 16, 2025
EPS Beat/Miss
—
Price Before
$0.93
Price After
$0.91
Q1 FY2025+2.27%
Report Date
Mar 14, 2025
EPS Beat/Miss
—
Price Before
$0.88
Price After
$0.90
Q4 FY2024+0.00%
Report Date
Dec 12, 2024
EPS Beat/Miss
—
Price Before
$0.87
Price After
$0.87
Q4 FY2024+3.67%
Report Date
Oct 24, 2024
EPS Beat/Miss
—
Price Before
$1.09
Price After
$1.13
Q2 FY2024+0.00%
Report Date
May 13, 2024
EPS Beat/Miss
—
Price Before
$1.15
Price After
$1.15
Avg Beat Reaction-10.05%
Beat Rate1 / 8 quarters
Largest Move-10.05% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HBP.TO ends December
Helix BioPharma Corp. (HBP.TO) most recently reported earnings on March 16, 2026 for Q1 FY2026, posting EPS of $-0.01 — beating the analyst consensus of $-0.10 by +90.9%. The next HBP.TO earnings date is expected around September 1, 2026.
Each quarter, investors track HBP.TO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HBP.TO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HBP.TO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HBP.TO earnings · 5 questionsHelix BioPharma Corp.'s next earnings report is expected around September 1, 2026. HBP.TO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HBP.TO historically reports after market close (AMC).
HBP.TO earnings datewhen is HBP.TO earningsHBP.TO next earnings datewhen does HBP.TO report earningsHBP.TO earnings calendar
▸ Source: FMP · Helix BioPharma Corp. SEC filings · US GAAP · Helix BioPharma Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026